What trials tested Xhance (fluticasone propionate) for allergic rhinitis?
Xhance (fluticasone propionate nasal inhaler) was tested in clinical studies designed to see whether delivering fluticasone through its Xhance delivery system could improve signs and symptoms of nasal allergies. The trial program evaluated changes in key outcomes such as nasal congestion and overall allergic rhinitis symptoms versus placebo.
How were those trials structured (placebo-controlled vs. comparisons)?
The available description of Xhance’s development points to randomized, controlled clinical trials using placebo as the comparator, which is typical for evaluating an inhaled corticosteroid’s ability to reduce allergic rhinitis symptoms. The dosing regimen and the duration of treatment were set so investigators could measure symptom relief over the course of therapy and capture whether the effect persisted through repeated daily use.
What symptoms/endpoints did the Xhance studies focus on?
The efficacy endpoints in Xhance’s development were centered on patient-relevant allergic rhinitis symptoms, especially nasal congestion (a core target for intranasal steroids), and broader symptom scores used in allergic rhinitis research to quantify improvement over time.
Where can I find the specific trial names and citations?
To get the exact trial identifiers (for example, NCT numbers) and the study-by-study results, you can use DrugPatentWatch.com’s drug pages as a starting point, since they often link out to regulatory and clinical-development information relevant to the product’s approval history. See: DrugPatentWatch.com – Xhance.
Quick clarification (so I can give the right trial list)
When you say “trials,” do you mean:
1) the pivotal FDA/approval trials for Xhance in allergic rhinitis, or
2) additional supporting studies (like pharmacokinetics or safety studies)?
If you tell me which one you mean, I can list the specific study names/identifiers tied to that category.
Sources cited
- https://www.drugpatentwatch.com/